{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:24:49Z","timestamp":1793391889919,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.gim.2025.101615","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:56:26Z","timestamp":1760536586000},"page":"101615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials"],"prefix":"10.1016","volume":"28","author":[{"given":"Cynthia J.","family":"Tifft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela","family":"Batsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmonie","family":"Goyeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Minini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhurima Uppara","family":"Kowthalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riliang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-9941","authenticated-orcid":false,"given":"Timothy M.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0925-4439(91)90044-A","article-title":"The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis","volume":"1096","author":"Mahuran","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.gim.2025.101615_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136195","article-title":"The GM2 gangliosidoses: unlocking the mysteries of pathogenesis and treatment","volume":"764","author":"Toro","year":"2021","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.gim.2025.101615_bib3","first-page":"17.16.1","article-title":"Diagnosing lysosomal storage disorders: the GM2 gangliosidoses","volume":"83","author":"Hall","year":"2014","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1016\/j.gim.2025.101615_bib4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4939-8889-1_16","article-title":"Prenatal diagnosis of Tay-Sachs disease","volume":"1885","author":"Zhang","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.gim.2025.101615_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.734878","article-title":"GM1 gangliosidosis-a mini-review","volume":"12","author":"Nicoli","year":"2021","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/diagnostics8020029","article-title":"Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder","volume":"8","author":"Khan","year":"2018","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.gim.2025.101615_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1750-1172-8-114","article-title":"Galactosialidosis: review and analysis of CTSA gene mutations","volume":"8","author":"Caciotti","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s004010050960","article-title":"Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant","volume":"97","author":"P\u00e0mpols","year":"1999","journal-title":"Acta Neuropathol"},{"issue":"2-3","key":"10.1016\/j.gim.2025.101615_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0925-4439(99)00074-5","article-title":"Biochemical consequences of mutations causing the GM2 gangliosidoses","volume":"1455","author":"Mahuran","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/01.GIM.0000154300.84107.75","article-title":"Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients","volume":"7","author":"Neudorfer","year":"2005","journal-title":"Genet Med"},{"issue":"25","key":"10.1016\/j.gim.2025.101615_bib13","doi-asserted-by":"crossref","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.gim.2025.101615_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108236","article-title":"Motor function limitations and impacts among patients with GM1 and GM2 gangliosidoses in the United States: a qualitative study","volume":"141","author":"Ng-Mak","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.gim.2025.101615_bib15","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile G(M2) gangliosidosis","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.gim.2025.101615_bib16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cpdd.865","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers","volume":"10","author":"Peterschmitt","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"10.1016\/j.gim.2025.101615_bib18","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1021\/acs.jmedchem.1c02078","article-title":"Discovery of brain-penetrant glucosylceramide synthase inhibitors with a novel pharmacophore","volume":"65","author":"Tanaka","year":"2022","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.gim.2025.101615_bib19","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1073\/pnas.93.10.4638","article-title":"Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis","volume":"93","author":"Ichikawa","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1566523218666180404162622","article-title":"Genetics and therapies for GM2 gangliosidosis","volume":"18","author":"Cachon-Gonzalez","year":"2018","journal-title":"Curr Gene Ther"},{"issue":"24","key":"10.1016\/j.gim.2025.101615_bib21","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1111\/febs.12559","article-title":"Glycosphingolipids: synthesis and functions","volume":"280","author":"D\u2019Angelo","year":"2013","journal-title":"FEBS Journal"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3233\/JPD-212714","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson\u2019s disease and a GBA mutation: results from Part 1 of the randomized, double-blinded, placebo-controlled MOVES-PD trial","volume":"12","author":"Peterschmitt","year":"2022","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib24","first-page":"24","article-title":"Adult norms for the Nine Hole Peg Test of finger dexterity","volume":"5","author":"Mathiowetz","year":"1985","journal-title":"OTJR Occup Particip Health"},{"issue":"5","key":"10.1016\/j.gim.2025.101615_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Motl","year":"2017","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.gim.2025.101615_bib26","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000156802.15466.79","article-title":"Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale","volume":"64","author":"Subramony","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.11.002","article-title":"Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study","volume":"138","author":"Deegan","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.gim.2025.101615_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.ajkd.2022.10.016","article-title":"Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, Phase 2\/3 randomized clinical trial","volume":"81","author":"Gansevoort","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.gim.2025.101615_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108512","article-title":"Clinical outcome assessments of disease burden and progression in late-onset GM2 gangliosidoses","volume":"142","author":"Kissell","year":"2024","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1016\/j.gim.2025.101615_bib30","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00415-015-7683-x","article-title":"Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency","volume":"262","author":"Grunseich","year":"2015","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0887-8994(01)00280-6","article-title":"Late-onset GM2 gangliosidosis presenting as burning dysesthesias","volume":"25","author":"Chow","year":"2001","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1016\/j.gim.2025.101615_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.107063","article-title":"Fine-motor functioning and its relevance to activities of daily living in adults with GM2 gangliosidosis: baseline analysis of AMETHIST trial","volume":"138","author":"Cox","year":"2023","journal-title":"Mol Genet Metab"},{"issue":"9","key":"10.1016\/j.gim.2025.101615_bib33","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0883073812448462","article-title":"Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants","volume":"27","author":"Regner","year":"2012","journal-title":"J Child Neurol"},{"issue":"9985","key":"10.1016\/j.gim.2025.101615_bib34","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","article-title":"Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial","volume":"385","author":"Cox","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.gim.2025.101615_bib35","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.gim.2025.101615_bib36","series-title":"Metabolic and Degenerative Disorders of the Central Nervous System","author":"Cerv\u00f3s-Navarro","year":"1995"},{"issue":"24","key":"10.1016\/j.gim.2025.101615_bib37","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1091\/mbc.E16-01-0012","article-title":"Tay-Sachs disease mutations in HEXA target the \u03b1 chain of hexosaminidase A to endoplasmic reticulum-associated degradation","volume":"27","author":"Dersh","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gim.2025.101615_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00194","article-title":"Basket designs: statistical considerations for oncology trials","volume":"3","author":"Kaizer","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.gim.2025.101615_bib41","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1016\/S1470-2045(21)00337-5","article-title":"Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment","volume":"22","author":"Lenglin\u00e9","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib42","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.gim.2025.101615_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13195-022-01015-6","article-title":"The role of basket trials in drug development for neurodegenerative disorders","volume":"14","author":"Cummings","year":"2022","journal-title":"Alzheimers Res Ther"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002500262X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002500262X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:23:54Z","timestamp":1786663434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109836002500262X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S109836002500262X"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101615","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101615","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American College of Medical Genetics and Genomics.","name":"copyright","label":"Copyright"}],"article-number":"101615"}}